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Abstract 
Background: Newcastle disease is a devastating disease in poultry caused by virulent Newcastle disease virus (NDV), 
a paramyxovirus endemic in many regions of the world despite intensive vaccination. Phylogenetic analyses reveal 
ongoing evolution of the predominant circulating genotype 2.VII, and the relevance of potential antigenic drift is 
under discussion. To investigate variation within neutralization-sensitive epitopes within the protein responsible 
for receptor binding, i.e. the Hemagglutinin-Neuraminidase (HN) spike protein, we were interested in establishing 
genotype-specific monoclonal antibodies (MAbs).
Methods: An HN-enriched fraction of a gradient-purified NDV genotype 2.VII was prepared and successfully 
employed to induce antibodies in BalbC mice that recognize conformationally intact sites reactive by haemagglu-
tination inhibition (HI). For subsequent screening of mouse hybridoma cultures, an NDV-ELISA was established that 
utilizes Concanavalin A (ConA-ELISA) coupled glycoproteins proven to present conformation-dependent epitopes.
Results: Six out of nine selected MAbs were able to block receptor binding as demonstrated by HI activity. One 
MAb recognized an epitope only present in the homologue virus, while four other MAbs showed weak reactivity to 
selected other genotypes. On the other hand, one broadly cross-reacting MAb reacted with all genotypes tested and 
resembled the reactivity profile of genotype-specific polyclonal antibody preparations that point to minor antigenic 
differences between tested NDV genotpyes.
Conclusions: These results point to the concurrent presence of variable and conserved epitopes within the HN 
molecule of NDV. The described protocol should help to generate MAbs against a variety of NDV strains and to enable 
in depth analysis of the antigenic profiles of different genotypes.
Keywords: Monoclonal antibody, Newcastle disease virus, Genotype 2.VII, Antigenicity, Hemagglutinin-
Neuraminidase protein, Conformational epitopes
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Introduction
Newcastle disease virus (syn. avian orthoavulavirus-1; 
avian paramyxovirus-1 (APMV-1), NDV) is a mem-
ber of the family of Paramyxoviridae within the genus 
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Orthoavulavirus, which together with the genera Meta- 
and Paraavulavirus form the subfamily Avulavirinae [1]. 
Like other members of the order of Mononegavirales, 
NDV is an enveloped virus with an RNA genome of neg-
ative polarity. The genome size of either 15,186, 15,192 or 
15,198 nucleotides [2] encodes for six structural proteins 
[3, 4] with two outer spike glycoproteins, the hemag-
glutinin-neuraminidase- (HN) and fusion protein (F), 
that facilitate attachment to and subsequent entry into 
the host cell. The latter protein is translated as a precur-
sor molecule (F0) and cleaved by cellular proteases into 
disulfide bond-linked subunits F1 and F2 [5, 6]. Both 
spike proteins are immunogenic and induce protective 
immunity in the host [7–9]. The dominating structural 
protein of the virion however is the nucleoprotein (NP), 
which enwraps the viral RNA into a helical capsid and 
together with the phospho (P)-protein and the large (L) 
protein forms the viral polymerase complex. The matrix 
(M) protein is positioned underneath the viral membrane 
and is considered to stabilize the virion architecture. In 
addition, two regulatory proteins, V and W, are inte-
grated into the virion [10, 11].
In poultry, virulent NDV strains induce Newcastle dis-
ease, a systemic infection with mortality of up to 100% in 
chickens. Introducing avirulent APMV-1 strains as ND 
vaccines in the late 1940ies was a hallmark for protect-
ing chickens and turkeys from disease [12], and today 
ND vaccination is fundamental for protecting poultry 
worldwide. Nevertheless, the disease is endemic in many 
regions of the world. Lately, inadequate protection by 
established but old vaccine strains against currently cir-
culating NDV strains has been proposed [13–15]. This 
hypothesis is supported by genetic analysis: Circulat-
ing NDV strains reveal a tremendous heterogeneity and 
strains can be divided into two genetic classes (1–2) with 
one (1.I) and 21 (2.I – 2.XXI) recognized genotypes, 
respectively [16]. Whereas the established vaccine strains 
belong to genotype 2.I and 2.II, genotype 2.VII domi-
nates the current panzootic in Asia and the Middle East 
[17, 18]. Homology between the two genotypes for F and 
HN spike proteins, responsible for eliciting protective 
immune response in the host [19], is low: 75–79% and 
71–75% on the nucleotide level and 85–89% and 84–88% 
on the level of amino acids. Despite the genetic variation, 
antigenically NDV still forms a single homogenous sero-
type [20, 21]. Based on the haemagglutination inhibition 
test (HI) that detects HN-specific antibodies that block 
virus binding to sialic acid receptors on erythrocytes or 
serum neutralization tests, polyclonal sera can differen-
tiate between serotypes of the subfamily Avulavirinae 
[22, 23] but cannot distinguish between NDV genotypes 
[21]. However, by monoclonal antibodies (MAbs) differ-
ences in specific epitopes have been recognized [24–26]. 
Profiling of a battery of MAbs raised against NDV-Ulster 
2 C (genotype 2.I.2) and pigeon type paramyxovirus 
(genotype 2.VI) to a total of 1526 NDV isolates allowed 
distinction of different groups but also revealed consid-
erable heterogeneity within groups [27]. Further studies 
with neutralizing MAbs to NDV strain Australia-Victoria 
(AV) (genotype 2.I.1.1) recognized seven different con-
formation dependent antigenic sites within the HN pro-
tein. Two sites conveyed virus neutralization only (sites 
3 and 4), while MAbs binding to other sites inhibited 
HA activity only (sites 1 and 14) or both HA and NA 
activity (sites 2, 12 and 23) [28–33]. Studies with MAbs 
established with the apathogenic strain NDV-D26 (geno-
type 2.I.1.1) established three different epitopes sensitive 
for both HI and NI activity of MAbs and mapped these 
sites to different amino acids when escape variants were 
analyzed [34]. Likewise HI-positive MAb AVS-I, raised 
against the avirulent LaSota vaccine strain (genotype 2.II) 
[35] mapped to aa residue 570 that was close to but not 
part of the other described epitopes [36]. This indicates 
that NDV strains might express at least slightly differ-
ent neutralizing epitope patterns. Information for such 
epitopes of NDV genotype 2.VII is not available.
In order to characterize antigenic sites of circulating 
NDV genotype 2.VII, we generated genotype-specific 
MAbs that are able to block biologically active sites of 
the HN protein, i.e. antibodies that are able to neutral-
ize infectivity and/or block HA activity. For this approach 
biophysically enriched HN protein fraction of purified 
virus proved to be an efficient antigen and the applied 
Concanavalin A (ConA)-ELISA technique that binds 
antigen not directly on the plate but coupled by the lec-
tin, provided a high throughput system suitable to detect 
antibodies to conformation sensitive sites. The result-
ing MAbs were used to recognize unique neutralizing 
epitopes of NDV genotype 2.VII.
Material and methods
Viruses and sera
NDV strain chicken/EGY/NR730/2016 (NR730; Gen-
Bank Acc. no. MH899939) was isolated from an ND 
vaccinated layer flock in Egypt suffering from respira-
tory distress. The virus was characterized as velogenic 
having an intracerebral pathogenicity index (ICPI) of 
1.8 and belonged to genotype 2.VII.1.1 (formerly 2.VIIb) 
[37]. Pigeon type paramyxovirus-1 (pigeon/Germany/
R75/1998), genotype 2.VI, was derived from the reposi-
tory of the ND reference laboratory at the FLI (Acc. No. 
KJ736742) and NDV/clone 30, genotype 2.II, was derived 
from a commercial vaccine (MSD, New Jersey, USA). 
As a source of polyclonal reference antibodies, watery 
egg yolk preparation from eggs from specific pathogen 
free (SPF) chickens was used, immunized repeatedly 
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with specified inactivated NDV antigens. A monospe-
cific rabbit α-NDV-HN serum and α-NDV-F serum [38] 
were used for specific detection of NDV-HN protein by 
western blot (WB) analysis. Immunizations were car-
ried out in accordance with the legally approved protocol 
(MV-LALLF- 7221.3–2.5–010/10).
Virus propagation and purification
Virus was propagated in embryonated SPF chicken 
eggs (ECE) as described [39] (VALO BioMedia GmbH, 
Osterholz-Scharmbeck, Lower Saxony, Germany). 
Amino-allantoic fluid (AAF) was harvested on day 3 post 
infection (dpi) and purified by sucrose gradient ultra-cen-
trifugation. Briefly, debris was cleared from AAF by low 
speed centrifugation (30  min at 10,976 × g; 10,000  rpm 
Rotor JA-10; Beckman Coulter, Brea, California, USA). 
Then virus was spun down by ultra-centrifugation (1.5 h 
at 96,281 × g; 28,000 rpm, 32Ti Rotor, Beckman Coulter). 
Virus pellets from 6 tubes were re-suspended in a total 
of 45 mL of phosphate buffered saline (PBS, pH 7.2) con-
taining 1  M KCl (KCl-PBS) before adding 15  mL of the 
virus suspension on top of a discontinuous sucrose gra-
dient (30–60%, in KCl-PBS). Visible bands forming after 
ultra-centrifugation overnight (96,281×g; 28,000  rpm, 
32Ti Rotor; Beckman Coulter) were collected and diluted 
1:5 in KCl-PBS before pelleting the virus by ultra-cen-
trifugation for 1.5 h (96,281×g; 28,000 rpm, 32Ti Rotor; 
Beckman Coulter). The final virus pellets, representing 
a total of 228  mL AAF were collected and resuspended 
in 1.5  ml KCl-PBS. The protein concentration of the 
obtained virus suspension was determined according 
to Bradford using the Roti®-Quant protein quantitation 
assay (Carl Roth GmbH, Karlsruhe, Baden-Württemberg, 
Germany) following the producer’s instructions. Hae-
magglutination activity was determined using the HA 
test according to standard procedures [39]. For antigen 
preparation of pigeon type paramyxovirus (PPMV-1) 
R75/98 and vaccine type APMV-1 clone 30 purification 
was done accordingly, but virus was resuspended in PBS.
Enrichment of HN protein
Separation of NDV spike proteins was done as described 
by [40]. Briefly, the protein concentration of the puri-
fied virus was adjusted to 1.5 mg/mL in KCl-PBS before 
0.1 mL Triton X-100 in PBS (20% (v/v)) was added, gen-
tly mixed and kept at room temperature (RT) for 20 min. 
The suspension was centrifuged (20  min at 10,000×g, 
9703 rpm, A-4-81-11 Rotor, (Eppendorf, Hamburg, Ger-
many)) and the obtained pellet (p1) was resuspended in 
1 mL PBS (0.01 M, pH 7.2) and kept for analysis, whereas 
the supernatant was further cleared by ultra-centrifuga-
tion at high speed (1 h at 200,000×g, 55,000 rpm Rotor 
TSL 55 (Beckman Coulter, Brea, California, USA)) for 
1 h. Again the pellet (p2) was kept for analysis after resus-
pension in 0.2  mL PBS. The supernatant was collected 
and dialyzed against 0.01  M phosphate buffer in order 
to remove the potassium chloride from the buffer used 
during purification. Any precipitate that formed dur-
ing dialysis was sedimented by centrifugation (20  min 
at 10,000×g, 9703  rpm, A-4-81-11 Rotor (Eppendorf, 
Hamburg, Germany)) and the pellet was resuspended in 
0.1 mL PBS (p3). The supernatant of the dialyzed mate-
rial (s3) was the fraction that was subsequently used as 
antigen for immunization.
SDS‑PAGE and western blot
Proteins were separated under denaturing conditions 
in 10% sodium dodecyl sulphate (SDS) polyacrylamide 
gels using a minigel system (Biorad, Hercules, California, 
USA) according to standard guides (http:// www. bio- rad. 
com/ webro ot/ web/ pdf/ lsr/ liter ature/ Bulle tin_ 6040. pdf ). 
Shortly, samples were diluted in sample buffer (Roti load® 
(Carl Roth GmbH, Karlsruhe, Baden-Württemberg, Ger-
many)) heated at 100  °C for five minutes before adding 
16 µL per lane into the gel pocket. Protein separation 
was conducted applying constant voltage setting (200 V) 
and the gel was either stained by Coomassie blue (Bio-
rad, Hercules, California, USA) or proteins were blotted 
on a nitrocellulose membrane (Amersham™ Protran, 
Cytiva, Marlborough, MA, USA) applying constant volt-
age setting (15 V) for 1.5 h. For western blot analysis the 
membrane was blocked for one hour with 1% skimmed 
milk powder in 0.025% Tween 20 in PBS (PBS-Tween) 
and subsequently incubated with target specific antibod-
ies over night at 4  °C. After washing three times with 
PBS-Tween, blots were incubated with peroxidase (POD) 
labeled species-specific anti-immune globulin G (IgG) 
or immune globulin Y (IgY) conjugates (Sigma-Aldrich, 
St. Louis, Missouri, USA) for 1  h at RT. After washing 
three times, peroxidase activity was visualized by chemi-
luminescence using SuperSignal West Pico Chemilu-
minescent Substrate (Thermo Scientific™. Waltham, 
Massachusetts, USA) and the Chemi Doc XRS + imaging 
system (Bio-Rad, Hercules, California, USA).
Mouse inoculation and monoclonal production
Two female BALB/c mice were immunized five times 
intraperitoneally with 20  µg of purified protein fraction 
(S3) mixed with an equal amount of GERBU Adjuvant 
MM (GERBU Biotechnik, Heidelberg, Germany) over a 
period of 26 weeks, with boost immunizations at weeks 
4, 7, 11 after the first administration, and four days before 
extraction of the spleen. Blood samples were taken from 
the submandibular vein on days 35, 49, and 84 after first 
immunization (dpi) and at 183 dpi, at the end of the 
experiment. Four days after the final boost mice had been 
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euthanized, their spleens were removed under aseptic 
conditions and splenocytes were harvested into serum-
free RPMI-1640 medium (Invitrogen, Carlsbad, Califor-
nia, USA/Thermo Scientific™. Waltham, Massachusetts, 
USA) by using a cell strainer (BD Biosciences, Franklin 
Lakes, New Jersey, USA). In the presence of polyethyl-
ene glycol 1500 (Roche Applied Science, Penzberg, Ger-
many) the isolated splenocytes were fused with murine 
myeloma SP2/0 cells following a slightly modified stand-
ard protocol [41] by using a cell-to-cell ratio of 1:4. Fused 
spleen cells were seeded in three different cell densities 
(30,000, 15,000, and 7,500 spleen cells per well, two plates 
per density) in 96well flat-bottomed plates (Greiner 
bio-one, Kremsmünster, Austria) and incubated for 
10 days (37 °C, 90% RH, and 5% CO2) by using complete 
RPMI-1640 culture medium 10% FCS (Fischer Scien-
tific, Hampton, New Hampshire, USA), 1 × MEM non-
essential amino acids, 2 mM L-glutamine, 1 mM sodium 
pyruvate (Invitrogen, Carlsbad, California, USA/Thermo 
Scientific™. Waltham, Massachusetts, USA) supple-
mented with 1 × BM Condimed H1 (Hybridoma Cloning 
Supplement, Sigma-Aldrich). For selection of growing 
hybridoma clones the complete medium was additionally 
supplemented with 1 × HAT Media Supplement (50×) 
Hybri-Max™ (Sigma-Aldrich). Growing cultures were 
screened for specific antibodies by Con-A ELISA, IF and 
HI. The haemaglutination inhibition test (HI) was used 
to determine the haemagglutination inhibition activity 
according to standard procedures [39]. For generating 
MAb producing cell clones, cells from positive cultures 
were cloned at least twice by limiting dilution (0.1 cells 
per well) in complete RPMI-1640 medium supplemented 
with 1 × HT Media Supplement (50 ×) Hybri-Max™ 
(Sigma-Aldrich). Final clones were adapted to complete 
RPMI-1640 medium without any further supplements.
Con‑A ELISA
The ELISA procedure was done according to a previ-
ously published protocol [42, 43]. Briefly, ELISA plates 
(Immunolon II, Thermo Scientific™. Waltham, Massa-
chusetts, USA) were pretreated with Concanavalin A 
(ConA) (Carl Roth GmbH) by adding 50  µl of Con-A 
(50 µg/mL in PBS) to each well. After incubation for 1 h 
at RT plates were washed three times using PBS-Tween 
and coated with 50 µL (20 µg/mL) pre-treated antigen. 
For preparation of the antigen, gradient purified virus 
stock at a concentration of 200  µg/mL was incubated 
with TritonX100 (1% v/v) for 45  min at RT and sub-
sequently diluted 1:10 with PBS for coating the plates 
for 1  h. Thereafter, plates were washed three times 
with PBS-Tween and blocked with 1% FCS in PBS for 
30  min at RT. Test sera (50 µL/well) at indicated dilu-
tions were incubated for 30 min at RT and after three 
washings with PBS-Tween, plates were incubated with 
POD labeled species specific anti-IgG or IgY conju-
gates (50 µL/well) for 30 min at RT. After washing the 
plates three times with PBS-Tween, bound antibod-
ies were visualized by incubation with o-Phenylenedi-
amine dihydrochloride (Sigma-Aldrich). (50 µL/(100 
µL/well, 1  mg/mL in 0.05  M phosphate-citrate buffer) 
for 20  min. Colour reaction was stopped with 2.5  M 
 H2SO4. Well density was measured at 492  nm using 
Sunrise™, Tecan’s microplate readers (Männedor) and 
the optical f, Zürich, Switzerland).
Indirect immunofluorescence (IF)
Immunofluorescence test was done with NDV/NR730/16 
infected LMH cells (ATCC CRL-2117™) cultivated in 96 
well plates (Corning, Corning, New York, USA) grown to 
70–80% confluency before infection. Infected plates were 
fixed with 3.7% formaldehyde after incubation for 24  h 
and stored at 4  °C for up to four weeks. For use, plates 
were emptied and treated with TritonX-100 (1% v/v) in 
PBS (100 µL/well) for 30  min at RT and after flicking 
off the supernatant, blocked with 1% fetal calf serum in 
PBS for 30 min at RT. Subsequently, cells were incubated 
with MAb or indicated sera (50 µL/well) for 1  h at RT. 
After washing the plates three times with PBS-Tween, 
wells were incubated with FITC-conjugated anti-species 
specific IgG or IgY conjugate (Sigma-Aldrich, coun-
try) for 1  h at RT. After final washing three times with 
PBS-Tween, wells were mounted with glycerol in water 
1:5 and inspected under the microscope (Eclipse TS100, 
Nikon, Minato, Tokyo, Japan) with the appropriate filter 
(excitation 495 nm, emission 525 nm).
Serum neutralization test (SNT)
Serial dilutions  (log2) of MAbs, starting with concen-
trated supernatants were mixed with equal volume of 
NDV/NR730/16 (100 µL) containing 400 tissue culture 
infectious dose 50  (TCID50). For each dilution row, the 
last well was kept without serum to serve as virus con-
trol. For each test a heat inactivated (56 °C, 30 min) NDV 
reference serum was included as positive neutralization 
control. After incubation for 30  min at 37  °C, 50 µL of 
antibody / virus mixture was transferred in triplicate to 
100 µL LMH cells that were cultivated without fetal calf 
serum but with TPCK treated Trypsin (2 µg/mL) (Sigma-
Aldrich) in 96well plates (Corning) at a density  106 cells/
cm2. The plates were incubated at 37  °C with 5%  CO2 
atmosphere for four days and SNT titer was determined 
by determining the last dilution without presence of a 
cytopathic effect (cpe) and calculated according to Reed 
and Muench [44].
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Haemagglutination inhibition test (HI)
Haemagglutination inhibition test was done according 
to standard procedures applying four haemagglutinating 
units, and HI titer are given as last serum dilution (log2) 
that inhibits agglutination [37]. For analyzing antigenic 
differences by polyclonal sera, the tests were done in trip-
licate and repeated in three independent experiments. 
Results were analyzed by Sigma Plot 11 (Systat Soft-
ware, INC) applying Kruskal–Wallis One Way Analysis 
of Variance on Ranks. R values were calculated accord-
ing to Archetti and Horsefall [45] with R: 0.5, 0.25, 0.13 




For the antigen preparation, gradient purified virus 
harvested from AAF (228  ml) was used, that yielded 
1.5 mL with an HA activity of 15  (log2) and a total pro-
tein content of 1.9  mg/mL. Purified virus preparations 
were dominated in SDS-PAGE and subsequent Coomas-
sie staining by a band at 55 kD, likely representing co-
migrating proteins of NP (53 kD), P (53–56 kD) and F1 
(55 kD) (Fig. 1a). This protein fraction is recognized as a 
major immunogenic fraction in the virion also by anti-
bodies of NDV vaccinated chicken (Fig. 1b). In addition, 
the HN protein is apparent as a ~ 70 kD band by Coomas-
sie staining (Fig.  1a) and in western blotting (Fig.  1b) 
as indicated by * in the figures. The identity of the HN 
protein with the observed ~ 70 kD band could be con-
firmed using a HN-monospecific hyper-immune serum 
in WB analysis (Fig.  1c). Likewise a minor band at ~ 40 
kD representing the M protein, was detected by Coomas-
sie staining (Fig.  1a) and polyclonal chicken antibodies 
in western blot analysis (Fig. 1b). After disruption of the 
virus with Triton and subsequent centrifugation (p1), 
proteins of the 55 kD bands were the dominant fraction 
of the pellet. Embedded in this band is the F1 protein that 
was specifically detected by an F-specific hyperimmune 
serum (Fig. 1d). Subsequent pellets (p2 and p3) and also 
the final supernatant (S3) still contained proteins of the 
55 kD band, detected by Coomassie staining (Fig. 1a) and 
western blot analysis (Fig. 1b). However, compared to the 
other proteins in these fractions, the 55 kD band was less 
prominent. During all centrifugation steps also HN pro-
tein was pulled down, but gradually became the domi-
nant fraction in the final supernatant that was used for 
the immunization (S3) and retained an HA activity of 13 
 (log2). On the other hand, the western blot analysis with 
the F-specific serum (Fig. 1d) indicated that the F1 pro-
tein was no longer present in these later fractions includ-
ing the final supernatant.
Establishing the ConA ELISA test system
Already after the first immunization of two BALB/c mice 
with the S3 fraction (20  µg/mouse), NDV specific anti-
bodies were detected in blood samples (Fig. 2a). Reactiv-
ity by HI (Fig. 2a, filled symbols) indicated that induced 
antibodies were able to block receptor mediated bind-
ing of the virus to erythrocytes, demonstrating that the 
antigen preparation represents conformationally intact 
epitopes of the HN protein. Antibody reactivity was also 
detected by ConA ELISA (Fig. 2a, transparent symbols). 
However, to verify that the ConA ELISA also detects 
antibodies to conformation dependent epitopes, the test 
system was checked with MAb 617/161 [46]. This MAb 
has HI activity against genotype 2.VI but not genotypes 
2.II or 2.VII, and does not react with denatured viral pro-
tein in western blot analyses. Hence, it is directed against 
a conformation-dependent epitope. In ConA-ELISA of 
plates coated with NDV genotype 2.II (clone 30), geno-
type 2.VI (pigeon/ DEU/R75/98) or genotype 2.VII 
chicken/EGY/ NR730/2016), the polyclonal reference 
antibody preparation was reactive with all three antigens 
(Fig. 3a). In contrast, but in agreement with the HI data, 
MAb 617/161 reacted only with genotype 2.VI antigen 
(Fig.  3b). Having established that the ConA-ELISA is 
suitable to detect antibodies to conformational epitopes 
within the HN protein of NDV, this assay was chosen for 












































Fig. 1 Preparation of HN-enriched fraction from purified NDV/
NR730/2016. Purified virus and fractions of the preparation were 
subjected to SDS-PAGE and subsequent Coomassie staining (a) and 
Western blot analysis using egg yolk preparation of a vaccinated 
chicken (b), HN specific rabbit hyperimmune serum (c) or F-specific 
rabbit hyperimmune serum (d). Beside the original gradient purified 
virus from AAF (V), the discarded pellets after Triton-100 treatment 
and two successive centrifugation steps (p1 and p2) are shown, 
together with the insoluble fraction after dialysis (p3) and the final 
supernatant used for immunisation (s3)
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Preparation of monoclonal antibodies
For the preparation of hybridoma cells, splenocytes of 
both mice were harvested four days after the 4th booster 
immunization, pooled, and half of the cells were used for 
the fusion. From a total of ten seeded 96well plates, 30 
wells yielded supernatants reactive in the Con A-ELISA 
with an OD reading above 0.2 (0.2–0.7), and virus-spe-
cific reactivity could be confirmed by IFT. Supernatants 
of 6 of the 30 wells also showed reactivity by HI to the 
homologue NDV NR730 (genotype 2.VII) (HI-titer (log2) 
between 1 and 5 and were chosen for subcloning and fur-
ther characterization. In addition, three HI-negative cul-
tures where chosen. Final supernatants from hybridoma 
cultures obtained after two rounds of cloning by limited 
dilution were subsequently used for the characterization. 
The 6 HI-positive hybridoma colonies showed reactivity 
by ConA-ELISA (Fig. 2b) and retained HI reactivity after 
single cell cloning (Table 1).
Analysis of cross reactivity reveals unique epitope patterns 
in the HN of genotype 2.VII
Initial analysis of the MAbs addressed the reactivity in 
different test systems and considered cross-reactivity to 
NDV vaccine strain clone 30, genotype 2.II. The majority 
of MAbs reacted specifically with the homologues geno-
type 2.VII virus (NR730) (Table 1). In addition, one of the 
HI-positive MAb (4E11) was able to block haemaggluti-
nation of clone 30 as well, although at two  log2 titer steps 
lower, compared to the homologous NR730 antigen. 
Reactivity was confirmed by IFT with specific reactivity 
with NR730 infected cells (Fig. 4b) and cross-reactivity to 
clone 30 for MAb 4E11, respectively (Table 1). By ConA-
ELISA, the HI-positive MAbs showed a strong reactivity 
to the homologous NR730 genotype VII virus (Fig.  2b) 
and again only MAb 4E11 cross-reacted with heterolo-
gous vaccine strain clone 30 (Table 1). In contrast, ConA-
ELISA reactivity of the three HI-negative MAbs was low 
(Fig. 2c). Interestingly, two MAbs (5B4, 6F2) reacted only 
with the homologous genotype 2.VII virus (NR730/16), 




Fig. 2 Antibody response of immunized mice and reactivity of 
obtained MAb. Antibody response of two mice immunized with 
the S3 antigen preparation were tested at indicated times after the 
first immunization by HI (filled symbols) and by ConA ELISA (white 
symbols) (a). Time of booster immunizations are given as triangles 
(filled triangle). In addition, ConA ELISA reactivity of HI positive MAbs 
(b) or HI-negative cloned MAbs (c) is given
◂
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2.II vaccine strain (clone30). This reactivity profile could 
be observed by ELISA (Table 1) and confirmed by west-
ern blot analysis (Fig.  4a): All three HI-negative MAbs 
reacted with virus proteins migrating at ~ 55 kD of NR730 
and, analogously to the ELISA, only MAb 1B6 showed 
cross-reactivity to clone 30. However, as NP, P and F1 
co-migrate on SDS-PAGE gels, it is not possible to draw 
conclusions with regard to the specificity of the MAbs 
from our western blot results. In contrast, none of the 
HI-positive MAbs were reactive by western blot analysis 
(Fig. 4a). The final test explored whether the MAbs were 
able to block infection of NR730 in LMH cells. By SNT 
four out of the six HI-positive MAbs neutralized viral 
infectivity at titers comparable to the HI test. In contrast, 
none of the three MAbs reactive with the 55 kD proteins 
were able to neutralize homologous NDV NR730.
For the six HI-positive MAbs we extended our analysis 
of cross-reactivity with six additional strains, represent-
ing class 1 and 2 viruses (Table  2). It became clear that 
the epitope recognized by MAb 4E11 was present in all 
genotypes tested and represents a well conserved site. For 
the other five HI-positive MAbs, reactivity profiles were 
highly specific for genotype 2.VII, even though one MAb 
(5C2) had residual reactivity to viruses from other geno-
types. This includes Herts 33/56, a very early NDV strain 
not assigned to a specific genotype within class 2 viruses 
and hence termed genotype 2.0. In addition, low level 







































Fig. 3 ConA-ELISA presents conformational dependent HN-epitope. Reactivity of MAb 617/161 recognizing specifically genotype 2.VI (PPMV-1) 
by HI, was tested against different antigens (PPMV-1: R75/98, 2.VII: NR730/16; 2.II: clone 30) by ConA- ELISA (b). Coating of plates was verified by 
homologue polyclonal chicken antibodies (a)
Table 1 Reactivity of obtained monoclonal antibodies (MAbs)
NR730: virulent Egyptian NDV isolate of genotype 2.VII, directly; clone 30: avirulent NDV vaccine strain of genotype 2.II
(#): directly coated ELISA plates; pos: positive reaction; neg: negative reaction
(*): deduced from western blot analysis due to co-migration of NP and P-protein
MAb HI (log2) IF ConA ELISA [OD 492] WB SNT (log2) Specificity
NR730 clone 30 NR730 clone 30 NR730 clone 30 NR730 clone 30 NR730
4E11 6 5 pos pos 1.79 1.19 neg n.d 8 HN
5C2 4 neg pos neg 1.69 0.17 neg n.d neg HN
5C9 4 neg pos neg 1.86 0.08 neg n.d 7 HN
5D1 3 neg pos neg 1.74 0.09 neg n.d 8 HN
7A8 5 neg pos neg 1.55 0.07 neg n.d neg HN
7C12 5 neg pos neg 2.04 0.08 neg n.d 8 HN
1B6 neg neg pos neg 0.18 0.18# 55 kD 55 kD neg NP/P*
5B4 neg neg pos neg 0.16 0.06# 55 kD neg neg NP/P*
6F2 neg neg pos neg 0.16 0.05# 55 kD neg neg NP/P*
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2.VI) and a recent virus of genotype 2.XIV from Nigeria. 
Apparently, also within genotype 2.VII there are anti-
genic differences: While three MAb (5C2, 5D1 and 7C12) 
were reactive with a second genotype 2.VII virus tested, 
reactivity of MAb 5C9 was fourfold lower with the heter-
ologous virus. For MAb 7C12 reactivity to heterologous 
dropped to 1 log2. In contrast, polyclonal antibody prep-
arations raised against genotypes 2.I, 2.II, 2.VI, 2.VII and 
2.XIV were reactive with all antigens tested (Additional 
file  1: Fig. S1). For the majority of antigens, titer differ-
ences of sera were in the range of 2  log2 steps. However, 
sera raised against genotype 2.I, 2.VI and 2.XIV, respec-
tively, had HI titer differences (dHI) of > 2  (log2) to indi-
vidual antigens, a discrimination not present with other 
sera. This is reflected when analyzing the antigenic rela-
tion of the five antigen / serum pairs (genotype 2.I, 2.II, 
2.VI, 2.VII and 2.XIV) by calculating the R values accord-
ing to Archetti and Horsfall [45]. The majority of R values 
were between 0.9 (genotype 2.I /2.II) and 0.25 (genotype 
2.VI / 2.XIV) (Additional file 2: Table S1). The highest R 
value was 0.15 (genotype 2.I /2.VI), resembling dHI of 
almost 3.
Discussion
HN‑enriched virus antigen induced antibodies 
to conformational epitopes
We report on the generation of MAbs to NDV that rec-
ognize genotype 2.VII specific epitopes on the HN pro-
tein. By enrichment of the HN protein fraction in the 
antigen preparation used for immunization of mice, 
we were able to obtain six hybridoma cultures that are 
reactive by HI, i.e. are able to block the receptor bind-
ing site of the HN protein on erythrocytes, and four of 
them neutralized viral infectivity in LMH cell cultures. In 
addition, three further selected hybridoma cultures nei-
ther showed HI nor neutralizing activity. By western blot 
analyses, these latter MAbs revealed reactivity against 
viral proteins that migrate at 55 kD and, hence, do not 
target HN. In the past, antibodies against NDV have been 
prepared by using whole, mostly gradient-purified virus 
preparations [24, 26, 47]. With this approach Lana and 
colleagues reported that five hybridoma fusion experi-
ments yielded 20 NDV specific MAbs, of which only 
three were reactive by HI. Earlier reports [35] obtained 
a single MAb from a total of 184 maintained hybridoma 
cultures that was specifically reactive with the homolo-
gous virus by HI. The described problems to obtain suf-
ficient numbers of MAbs reactive with ND spike proteins 
might in part be explained by the composition of the 
viral particle, which is dominated by the highly immu-
nogenic NP protein that fills the entire inner virion [48]. 
In addition, the M protein, forming an array underneath 
the viral membrane is abundant in the virion [49]. Both 
proteins account for ~ 30% of the virus-specific molecu-
lar masses in gradient-purified viral preparations when 
analyzed by nano-LC MALDI-TOF/TOF mass spectrom-
etry, and only about 10% of the virion are HN molecules 
[11; Karger personal communication]. By disrupting gra-
dient-purified virus by Triton X-100 (2%) and 1 M KCl, 
Nishikawa and colleagues could increase the fraction of 
HI reactive HN-specific MAbs, retrieving 9 out of a total 
of 21 [50]. Our method also used Triton X-100 and KCl 
disruption, but we subsequently applied ultracentrifuga-
tion to enrich HN and deplete M and NP proteins. This 
procedure was able to pull down a high proportion of the 
proteins that migrate as a 55 kD band including the NP. 
The subsequent steps reduced the proportion of the 55 
kD proteins further, but were not sufficient to remove all 
of the proteins: A slight band was still visible by Coomas-
sie-staining (Fig. 1a) and reacted with the polyclonal anti-
body preparation from a ND vaccinated chicken (Fig. 1b). 
This might be a result of incomplete separation of the 
interaction of the HN protein with the NP protein via 
the matrix protein [51]. Accordingly, three of the selected 
MAbs were reactive with the 55 kD band by western blot 



















































Fig. 4 Analysis of reactivity profile of MAbs. All MAbs were tested 
by WB-analysis (a). Boxes are giving results of the HI-reactive MAbs 
(left) and HI-negative MAbs (right). Beside testing with homologous 
virus antigen (NR750/16 genotype 2.VII), cross-reactivity of MAb (1B6) 
to genotype 2.II NDV was confirmed with heterologous clone 30 
antigen. Besides reactivity was tested by IFT with the homologous 
virus NR750/16 (b)
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serum (Fig.  1d) identified that a large proportion of 
the F1 protein was in the very first pellet of the antigen 
preparation, indicating that F protein was not part of the 
antigen. This would be in line with results of co-immuno-
precipitation experiments, showing a direct interaction 
of F and NP and HN and M [51]. Thus, it is likely that 
the three HI-negative MAbs are directed against NP or 
P protein. Further studies on protein specificity will have 
to address this question and evaluate potential potency 
in diagnostic approaches. Harsher conditions for parti-
cle disruption might have yielded an improved depletion 
of nucleocapsid proteins but, at the same time, may have 
denatured HN and destroyed HI epitope conformation.
Overall our aim to produce MAbs capable to block bio-
logically active sites of the HN protein of genotype 2.VII 
NDV by using an HN-enriched fraction of purified virus 
proved to be successful. We obtained a sufficient num-
ber of HI-positive MAbs already with a single fusion 
experiment, and two thirds of the selected hybridoma 
cultures yielded HN-specific MAbs that were able to 
block receptor binding.
ConA‑ELISA presents biologically intact and relevant 
antigenic sites of NDV
Due to the complex structure of biologically relevant 
epitopes of the homo-tetrameric HN protein [52–54], 
the approach to generate MAbs reactive with biologically 
activesites depends on native HN protein with the correct 
conformation, ideally from virus produced in eukaryotic 
cells ensuring bona fide glycosylation and folding. Reas-
suring evidence was obtained through the HI-positive 
antibody response of two mice immunized with enriched 
HN preparations. However, in order to select the appro-
priate antibodies, the screening system has to present the 
test antigen in its native conformation. When using the 
indirect ELISA techniques, immobilizing antigen directly 


















4E11 2.VII 5 6 4 5 4 5 6 7 6
5C2 2.VII neg 3 neg neg neg 2 4 7 3
5C9 2.VII neg neg neg neg neg neg 4 2 neg
5D1 2.VII neg neg neg neg neg neg 3 4 neg
7A8 2.VII neg neg neg neg neg neg 5 1 neg
7C12 2.VII neg neg neg neg neg neg 5 4 neg




a-Ulster 2.I 8.2 9.2 10.1 10.3 9.5 6.3 7.4 6.1 9.5
a-clone 
30b 2.II 7.0 8.8 8.3 8.8 8.3 7.0 7.6 7.7 8.2
a-R151/94 2.VI 6.2 8.5 6.3 5.9 6.2 8.1 7.8 7.7 7.0
a-NR 
730/16 2.VII 10.9 10.0 10.2 10.2 10.2 9.9 11.2 11.0 10.4
a-NR 
81/18 2.XIV 5.9 7.8 6.3 6.6 6.1 7.4 6.0 8.1 8.5
a: Sera were raised in SPF-chicken by immunizing with ß-Propiolacton inactivated virus preparations from 
SPF-eggs
b: yolk preparations form imunized SPF-chicken; c: genotype nomenclature according to 
Dimitrov et al. 2019 [16]
1: mallard/GER/R2919/2006; 2: Herts33/56 (PEI: PEI-AY170140)*  3: chicken/IRL/Ulster/1967; 4: 
vaccine/clone 30; 
5: JPN/Miyadera/1951;6: pigeon/GER/R75/1998; 7: chicken/EGY/NR730/2016; 8: 
chicken/IRN/NR1468/2012; 9:chicken/NGA/NR81/2018;  (country code alpha-3 according to ISO 3166 )
bold boxes indicate homologues serum / antigen pairs
* unassigned class 2 virus [2]                   differences between HI-titer to 
homologous antigen (dHI)
≤1 1-≤2: >2-≤3 <3
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to the plastic surfaces of the plates likely interferes with 
the conformational integrity of the antigen, and impor-
tant epitopes may be unpredictably masked or exposed 
[55]. To avoid such structural alterations caused by the 
coating, Russel and colleagues used NDV infected and 
formalin fixed cells with indirect immunoperoxidase test 
to visualize specific reactivity [25]. Having the advantage 
that already staining pattern in this test may give an indi-
cation whether MAbs are directed to outer glycoproteins, 
the test depends on manual inspection of the plates and 
is more difficult to standardize; in addition, use of for-
malin may denature sensitive epitopes. To be able to use 
ELISA technique for high throughput screening, investi-
gators have used antibody- or poly L-lysine-coated plates 
to capture and thereby preserve the conformation of a 
viral protein [56, 57]. Our test system relied on the lectin 
properties of ConA as an anchor for the antigen, a system 
previously shown to preserve conformational epitopes 
of viral glycoproteins [42, 43]. By using a genotype 2.VI 
specific monoclonal antibody that is highly reactive by 
HI [46], we could demonstrate that the ConA-ELISA 
preserves NDV epitopes sensitive to receptor blocking. 
Applying the Con-A-ELISA for screening of the initial 
hybridoma supernatants and subsequent cloning, we 
obtained six MAb that were reactive by ELISA and HI, 
and all six clones could be confirmed by IFT. However, 
none of the six HI-positive MAb were reactive by WB, 
which is in line with previous studies that denaturing 
WB conditions destroyed the conformation of HI sen-
sitive epitopes of the HN molecule. Overall, comparing 
ELISA reactivity to HI titers, it became apparent that 
ConA-ELISA was far more sensitive producing titers of 
well above 1:3200, whereas the highest HI titer was 1:256 
(8  log2) but without a direct correlation between the two 
values. It is striking that the MAb with the lowest HI titer 
(5C2) had comparable or even higher ELISA reactiv-
ity than the other MAbs. The ConA-ELISA, in addition, 
was able to present strain specific epitopes, as five out 
of six HI-positive MAbs reacted only with NDV geno-
type 2.VII strain NR730 but not with the vaccine strain 
clone 30, genotype 2.II, by HI. Thus, using HN-enriched 
virus preparation in conjunction with ConA-ELISA sys-
tem that preserves conformational epitopes proved to 
be efficient to produce specific MAbs that are suitable 
to identify biologically relevant targets in specific NDV 
genotypes.
HN‑specific MAbs distinguish strain‑specific and broadly 
cross reacting epitopes
In order to investigate the putative conservation of HI-
sensitive epitopes of HN proteins of ND viruses of differ-
ent genotypes we extended the analysis to cross-reactivity 
using NDV strains representing distantly related class 1 
NDV as well as seven additional class 2 genotype viruses. 
Only MAb 4E11 was reactive with all 8 different NDV 
genotypes tested, including the class 1 strain. On the 
other hand, the majority of HN specific MAbs predomi-
nantly reacted with the homologous NDV strain NR730, 
although within this group of MAbs three distinct reac-
tivity profiles were discernable: (a) MAb 5C2 showed 
residual cross-reactivity to three other genotypes, (b) 
three MAbs (5C9, 5D1, 7C12) reacted specifically with 
two different genotype 2.VII strains, and (c) MAb 7A8 
differentiated between the two genotype 2.VII viruses. 
This points, in summary, to a high degree of flexibility 
of some HI epitopes, whereas other epitopes seem to be 
very well preserved. This is corroborated by observations 
derived from structural analysis of the HN molecule: 
Crenell and colleagues found that MAbs could interfere 
with receptor binding, even though the target was not 
the receptor binding pocket itself [52]. In consequence 
such sites might not be crucial for the function of the 
molecule and are allowed to have more structural flex-
ibility. Intrinsic properties of antibodies targeting these 
sites might then influence the specificity of the reaction, 
i.e. antibodies with high affinity might be able to bind a 
broader spectrum of virus strains. On the other hand, 
epitopes adjacent to or directly at the receptor binding 
site are part of functionally pivotal structures and have 
to stay conserved. These epitopes would represent con-
served antigenic sites across the genotypes as recognized 
by the MAb 4E11 which showed HI and neutralization 
activity. In the viral HN antigen used for immunizing the 
mice, both types of sites were apparently immunogenic. 
Considering the number of obtained MAb, i.e. five strain 
specific versus one MAb specific for a conserved site, 
the variable sites might have been more immunogenic 
for mice. In contrast, polyclonal antibody preparations 
revealed only minor antigenic differences, indicating a 
balanced presentation of conserved and strain-/geno-
type-specific antigenic sites for chickens. In consequence 
polyclonal sera are of limited value when addressing vari-
ability of antigenic sites. On the other hand, polyclonal 
sera raised after immunization of chickens are capable to 
react to (and neutralize) a broad range of different NDV 
genotypes; this in turn may also relate to cross-protection 
against currently circulating field strains after vaccination 
with genotypically distant strains.
Conclusion
Further studies on epitope mapping of MAbs will help 
to elucidate these specific epitopes. It will be interest-
ing to learn whether genotype-specific antibodies rec-
ognize known binding sites but have a different amino 
acid configuration or whether the genotype 2.VII 
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specific epitopes are formed by different sites. Overall 
our studies highlight the value of MAb to dissect anti-
genic sites. The established MAbs are the first step to 
define genotype 2.VII specific neutralizing sites of NDV 
based on sequence information and should enable phy-
logenic analysis of antigenic sites in the future, a pre-
requisite to elucidate whether antigenic drift was the 
driving factor for evolution of NDV. In addition, well 
defined MAbs serve as valuable diagnostic tools to spe-
cifically detect NDV antigen for example in lateral flow 
devices or can be used for serological tests. When, for 
example, applied in blocking ELISA systems genotype 
specific reagents would allow to differentiate infected 
from vaccinated individuals (DIVA) by specifically 
detecting genotype 2.I, 2.II or 2.VII specific antibodies. 
The presented work flow provides a powerful method 
to generate and characterize these reagents.
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